1415637-72-7
1415637-72-7 结构式
基本信息
PF-05085727 >=98% (HPLC)
4-(AZETIDIN-1-YL)-1-METHYL-3-(1-METHYL-5-(4-(TRIFLUOROMETHYL)PHENYL)-1H-PYRAZOL-4-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDINE
1H-Pyrazolo[3,4-d]pyrimidine, 4-(1-azetidinyl)-1-methyl-3-[1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/08/19 | HY-102050 | PF-05085727 PF-05085727 | 1415637-72-7 | 5mg | 800元 |
| 2024/08/19 | HY-102050 | PF-05085727 PF-05085727 | 1415637-72-7 | 10mM * 1mLin DMSO | 880元 |
| 2024/08/19 | HY-102050 | PF-05085727 PF-05085727 | 1415637-72-7 | 10mg | 1250元 |
常见问题列表
|
PDE2A 2 nM (IC 50 ) |
PF-05085727 shows weak activity with IC 50 of 162 μM to induce cell death in a cellular toxicity assay using transformed human liver endothelial (THLE) cells.PF-05085727 (3 μM) shows a minimal inhibition of cytochrome P450 enzymes (CYPs), inhibits 1A2, 2C8, 2C9, 2D6 and 3A4 with percentage% of 16%, 18%, 7%, 4%, and 30%, respectively.PF-05085727 (10 μM) inhibits PDE1B, PDE4B, PDE7B and PDE10A with IC 50 values of 12.146 μM, 22,503 μM, 13.157 μM and 6.515 μM, respectively.
PF-05085727 (subcutaneous injection; 3.2 mg/kg/mice; 3 mg/kg/rat) gives a ratio of unbound brain (C bu ) to unbound plasma (C pu ) of ca. 0.27 and 0.37, respectively.PF-05085727 in mice leads to an acute and exposure-dependent elevation in the accumulation of bulk levels of cGMP in cortex, striatum, and hippocampus as measured by enzyme-linked immunosorbent assay.